Stock Market News1 month KRYS Stock Down on Initial Clinical Updates on KB407 & KB408 Zacks
Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.
XKrystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408, which are being developed to treat rare respiratory diseases.
X